- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03046992
Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Study Overview
Detailed Description
This is a first time in patient study primarily designed to evaluate the safety, tolerability, and efficacy of YH25448 in in patients with EGFR mutation positive (EGFRm+) advanced NSCLC with or without asymptomatic brain metastasis who progressed following prior therapy with an EGFR TKIs agent. This study is composed of 3 parts; part A is a dose escalation phase, part B is a dose expansion phase and part C is a dose extension phase.
In dose escalation phase, YH25448 will be escalated to reach either a maximum tolerated or absorbable dose in patients as defined by dose-limiting toxicity in NSCLC patients who progressed following prior EGFR TKIs treatment to evaluate the safety and tolerability. In dose expansion phase, further safety, tolerability, pharmacokinetic(PK) and efficacy will be evaluated at each dose level(s) of dose escalation phase in NSCLC patients who progressed following prior EGFR TKIs treatment and harbouring confirmed T790M mutation. In dose extension phase, additional 2 cohorts (2nd line therapy cohort, 1st line therapy cohort) will be enrolled to further assess the efficacy, safety, tolerability, and PK of YH25448 at the maximum tolerated dose (MTD) or recommended dose (RD) defined through dose escalation phase and dose expansion phase. Results of these studies will serve as the evidence for further clinical development.
This study will also characterize the metabolite(s) profile of YH25448 and determine PK of its metabolite(s) in biological samples if necessary. Also, exploratory correlation between biomarker profiles and pharmacokinetics/pharmacodynamics will be analyzed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 48108
- Inje University Haeundae Paik Hospital
-
Incheon, Korea, Republic of, 21565
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Severance Hospital
-
Seoul, Korea, Republic of, 03181
- Kangbuk Samsung Hospital
-
Seoul, Korea, Republic of, 07061
- SMG-SNU Boramae Medical Center
-
Ulsan, Korea, Republic of, 44033
- Ulsan University Hospital
-
-
Chungcheongbuk-do
-
Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 28644
- Chungbuk National University Hospital
-
-
Gyeonggi-do
-
Bucheon-si, Gyeonggi-do, Korea, Republic of, 14647
- The Catholic University of Korea, Bucheon St. Mary's Hospital
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 03080
- National Cancer Center
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Seoul National University Bundang Hospital
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13496
- CHA Bundang Medical Center, CHA University
-
Suwon-si, Gyeonggi-do, Korea, Republic of, 16247
- The Catholic University of Korea, St. Vincent's Hospital
-
-
Gyeongsangnam-do
-
Jinju-si, Gyeongsangnam-do, Korea, Republic of, 52727
- Gyeongsang National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 3 months.
- At least one measurable extracranial lesion, not previously irradiated and not chosen biopsy during the study screening period.
- Prior to enrolling in the study, patients must have central confirmation of T790M+ mutation status from a sample taken after documented progression on the EGFR-TKIs therapy according to cohort.
Exclusion Criteria:
- Spinal cord compression.
- Brain metastases with symptomatic and/or requiring steroid for at least 2 weeks prior to start of study treatment.
- Known intracranial hemorrhage which is unrelated to tumor.
- Central Nervous System (CNS) complications that require urgent neurosurgical intervention (e.g. resection or shunt placement).
- Leptomeningeal metastasis prior to study treatment.
- Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
Any cardiovascular disease as followed.
- History of symptomatic congestive heart failure (CHF) or serious cardiac arrhythmia requiring treatment
- History of myocardial infarction or unstable angina within 6 months of the first dose of study treatment
- Left ventricular ejection fraction (LVEF) < 50%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YH25448
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability by Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Time Frame: Safety and tolerability profile will be collected from baseline until 28 days after the last dose, expected average 1 year.
|
To assess the safety and tolerability profile of YH25448 by Common Terminology Criteria for Adverse Events (CTCAE) v4.03; vital signs (blood pressure, pulse, weight); laboratory parameters (clinical chemistry, hematology, urinalysis); physical examination; centrally reviewed electrocardiograms (ECGs), echocardiogram or multiple gated acquisition scan and performance status.
|
Safety and tolerability profile will be collected from baseline until 28 days after the last dose, expected average 1 year.
|
Objective Response Rate (ORR)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Per Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) assessed by MRI or CT.
ORR is the percentage of patients with at least 1 visit response of Complete Response (CR) or Partial Response (PR) (according to independent review), prior to progression or further anti-cancer therapy.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DoR)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Disease Control Rate (DCR)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Progression-Free Survival (PFS)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT.
Kaplan-Meier plots will be used to summarize the progression-free survival.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Overall Survival (OS)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Tumor shrinkage
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Objective Intracranial Response Rate (OIRR)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Duration of Intracranial Response (DoIR)
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Intracranial Progression Free Survival (IPFS).
Time Frame: At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
To obtain assessment of anti-tumor activity of YH25448 by evaluation of tumor response using RECIST version 1.1.
Kaplan-Meier plots will be used to summarize the progression-free survival.
|
At baseline and every 6 weeks from first dose objective disease progression or withdrawal from study, up to approximately 1 year.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yuhan Corporation, Clinical Development Department
Publications and helpful links
General Publications
- Kim B, Lee J, Jang H, Lee N, Mehta J, Jang SB. Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Adv Ther. 2022 Oct;39(10):4757-4771. doi: 10.1007/s12325-022-02286-z. Epub 2022 Aug 13.
- Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24. Erratum In: J Thorac Oncol. 2022 Oct 22;:
- Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. Erratum In: Lancet Oncol. 2020 Feb;21(2):e70.
- Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Apr 15;25(8):2575-2587. doi: 10.1158/1078-0432.CCR-18-2906. Epub 2019 Jan 22.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- YH25448-201 (Other Identifier: Yuhan Corporation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on EGFR Gene Mutation
-
Fujian Cancer HospitalUnknown
-
Fujian Cancer HospitalUnknown
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene MutationUnited States
-
University of VirginiaActive, not recruitingReal-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAFUnited States
-
ETOP IBCSG Partners FoundationAstraZenecaActive, not recruitingNSCLC Stage IV | EGFR Gene MutationSingapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
-
Hospital Erasto GaertnerAstraZenecaCompletedLung Neoplasms | KRAS Gene Mutation | EGFR Gene MutationBrazil
-
Shanghai Chest HospitalJiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruitingLung Cancer | EGFR Gene Mutation
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
Clinical Trials on YH25448
-
Yuhan CorporationSeoul National University HospitalCompletedNon-Small Cell Lung CancerKorea, Republic of
-
Janssen Research & Development, LLCCompletedHealthy | Hepatic ImpairmentGermany
-
Jin Hyoung KangRecruitingLung NeoplasmsKorea, Republic of
-
Janssen Research & Development, LLCYuhan CorporationCompletedCarcinoma, Non-Small-Cell LungUnited Kingdom, United States, Spain
-
Yuhan CorporationCompleted
-
Yuhan CorporationActive, not recruitingNon-Small Cell Lung CancerHungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
-
Jin Hyoung KangKorea University Anam HospitalNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
Janssen Research & Development, LLCRecruitingAdvanced Solid MalignanciesUnited States, Korea, Republic of, Canada, United Kingdom
-
Janssen Research & Development, LLCActive, not recruitingAdvanced or Metastatic Non-small Cell Lung CancerItaly, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
-
Janssen Research & Development, LLCActive, not recruitingNon-Small-Cell Lung CancerUnited States, France, Taiwan, United Kingdom, China, Spain, Japan, Australia, Korea, Republic of, Canada